Clinical Trial of Intranasal Delivery of NT-301

NCT06954428 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Tolerability of NT-301 Nasal Spray
Pharmacokinetics of NT-301 Nasal Spray
Safety of NT-301 Nasal Spray
Performance of NT-301 Nasal Spray Device

Interventions

COMBINATION_PRODUCT: NT-301 1 mg
COMBINATION_PRODUCT: NT-301 2 mg
COMBINATION_PRODUCT: Placebo 1 mg
COMBINATION_PRODUCT: Placebo 2 mg
COMBINATION_PRODUCT: Placebo 3 mg
COMBINATION_PRODUCT: NT-301 3 mg
COMBINATION_PRODUCT: NT-301 4 mg
COMBINATION_PRODUCT: Placebo 4 mg
DRUG: Active Comparator: Movapo pen
DRUG: Experimental: BA NT-301 strength 4 mg

Sponsor

Nano PharmaSolutions Australia

Collaborators

[object Object]
[object Object]